The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies (Q37365776): Difference between revisions
Jump to navigation
Jump to search
Added reference to claim: publication date (P577): 30 September 2013, #quickstatements; #temporary_batch_1571251878538 |
Changed label, description and/or aliases in es: BOT - Adding descriptions (1 languages): es |
||||||||||||||
(48 intermediate revisions by 8 users not shown) | |||||||||||||||
label / en | label / en | ||||||||||||||
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies | The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies | ||||||||||||||
label / nl | label / nl | ||||||||||||||
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies | The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies | ||||||||||||||
label / ast | label / ast | ||||||||||||||
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies | |||||||||||||||
description / ast | description / ast | ||||||||||||||
artículu científicu espublizáu en 2013 | |||||||||||||||
description / es | description / es | ||||||||||||||
artículo científico publicado en 2013 | |||||||||||||||
Property / title | Property / title | ||||||||||||||
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies (English) | |||||||||||||||
Property / instance of: review article / reference | |||||||||||||||
Property / instance of: review article / reference | |||||||||||||||
Property / instance of: review article / reference | |||||||||||||||
Property / instance of: review article / reference | |||||||||||||||
Property / instance of: review article / reference | |||||||||||||||
Property / instance of: review article / reference | |||||||||||||||
Property / instance of: review article / reference | |||||||||||||||
Property / published in: Journal of Hematology & Oncology / reference | |||||||||||||||
stated in: PubMed Central retrieved: 18 October 2019
| |||||||||||||||
Property / published in: Journal of Hematology & Oncology / reference | |||||||||||||||
stated in: PubMed Central retrieved: 15 December 2019
| |||||||||||||||
Property / published in: Journal of Hematology & Oncology / reference | |||||||||||||||
stated in: PubMed Central retrieved: 22 July 2020
| |||||||||||||||
Property / published in: Journal of Hematology & Oncology / reference | |||||||||||||||
stated in: PubMed Central retrieved: 17 October 2022
| |||||||||||||||
Property / publication date: 30 September 2013 / reference | |||||||||||||||
stated in: PubMed Central retrieved: 18 October 2019
| |||||||||||||||
Property / publication date: 30 September 2013 / reference | |||||||||||||||
stated in: PubMed Central retrieved: 15 December 2019
| |||||||||||||||
Property / publication date: 30 September 2013 / reference | |||||||||||||||
stated in: PubMed Central retrieved: 22 July 2020
| |||||||||||||||
Property / publication date: 30 September 2013 / reference | |||||||||||||||
stated in: PubMed Central retrieved: 17 October 2022
| |||||||||||||||
Property / main subject | |||||||||||||||
Property / main subject: patient / rank | |||||||||||||||
Property / main subject | |||||||||||||||
Property / main subject: hematologic cancer / rank | |||||||||||||||
Property / main subject: hematologic cancer / reference | |||||||||||||||
Property / main subject: hematologic cancer / reference | |||||||||||||||
Property / main subject: hematologic cancer / reference | |||||||||||||||
Property / main subject: hematologic cancer / reference | |||||||||||||||
Property / main subject | Property / main subject | ||||||||||||||
Property / copyright license: Creative Commons Attribution 2.0 Generic / reference | |||||||||||||||
stated in: Europe PubMed Central retrieved: 18 October 2019
| |||||||||||||||
Property / copyright license: Creative Commons Attribution 2.0 Generic / reference | |||||||||||||||
stated in: Europe PubMed Central retrieved: 15 December 2019
| |||||||||||||||
Property / copyright license: Creative Commons Attribution 2.0 Generic / reference | |||||||||||||||
stated in: Europe PubMed Central retrieved: 22 July 2020
| |||||||||||||||
Property / copyright license: Creative Commons Attribution 2.0 Generic / reference | |||||||||||||||
stated in: Europe PubMed Central retrieved: 17 October 2022
| |||||||||||||||
Property / cites work | |||||||||||||||
Property / cites work: Association between single nucleotide polymorphism of PD-L1 gene and non-small cell lung cancer susceptibility in a Chinese population / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / cites work: Association between single nucleotide polymorphism of PD-L1 gene and non-small cell lung cancer susceptibility in a Chinese population / reference | |||||||||||||||
stated in: PubMed reference URL: https://pubmed.ncbi.nlm.nih.gov/24283718 retrieved: 12 December 2020
based on heuristic: inferred from PubMed ID database lookup | |||||||||||||||
Property / cites work | |||||||||||||||
Property / cites work: A cell culture model for T lymphocyte clonal anergy / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / cites work: A cell culture model for T lymphocyte clonal anergy / reference | |||||||||||||||
stated in: PubMed reference URL: https://pubmed.ncbi.nlm.nih.gov/24283718 retrieved: 12 December 2020
based on heuristic: inferred from PubMed ID database lookup | |||||||||||||||
Property / cites work | |||||||||||||||
Property / cites work: Restricted TRBV repertoire in CD4+ and CD8+ T-cell subsets from CML patients / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / cites work: Restricted TRBV repertoire in CD4+ and CD8+ T-cell subsets from CML patients / reference | |||||||||||||||
stated in: PubMed reference URL: https://pubmed.ncbi.nlm.nih.gov/24283718 retrieved: 12 December 2020
based on heuristic: inferred from PubMed ID database lookup | |||||||||||||||
Property / cites work | |||||||||||||||
Property / cites work: Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / cites work: Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL / reference | |||||||||||||||
stated in: PubMed reference URL: https://pubmed.ncbi.nlm.nih.gov/24283718 retrieved: 12 December 2020
based on heuristic: inferred from PubMed ID database lookup | |||||||||||||||
Property / cites work | |||||||||||||||
Property / cites work: Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / cites work: Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis / reference | |||||||||||||||
stated in: PubMed reference URL: https://pubmed.ncbi.nlm.nih.gov/24283718 retrieved: 12 December 2020
based on heuristic: inferred from PubMed ID database lookup | |||||||||||||||
Property / main subject | |||||||||||||||
Property / main subject: T-lymphocytes / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / main subject: T-lymphocytes / reference | |||||||||||||||
Property / main subject | |||||||||||||||
Property / main subject: CD274 molecule / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / main subject: CD274 molecule / reference | |||||||||||||||
Property / main subject | |||||||||||||||
Property / main subject: tumor of hematopoietic and lymphoid tissues / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / main subject: tumor of hematopoietic and lymphoid tissues / reference | |||||||||||||||
Property / main subject: tumor of hematopoietic and lymphoid tissues / reference | |||||||||||||||
Property / Dimensions Publication ID | |||||||||||||||
Property / Dimensions Publication ID: 1051135651 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / copyright status | |||||||||||||||
Property / copyright status: copyrighted / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / language of work or name | |||||||||||||||
Property / language of work or name: English / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / language of work or name: English / reference | |||||||||||||||
Latest revision as of 20:01, 31 July 2024
scientific article published on 30 September 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies |
scientific article published on 30 September 2013 |
Statements
1 reference
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies (English)
1 reference
Li Shi
1 reference
Shaohua Chen
1 reference
Lijian Yang
1 reference
Yangqiu Li
1 reference
30 September 2013
10 references
3 April 2019
18 June 2019
19 June 2019
31 July 2019
12 October 2019
18 October 2019
15 December 2019
22 July 2020
17 October 2022
10 references
3 April 2019
18 June 2019
19 June 2019
31 July 2019
12 October 2019
18 October 2019
15 December 2019
22 July 2020
17 October 2022
9 references
3 April 2019
18 June 2019
19 June 2019
31 July 2019
12 October 2019
18 October 2019
15 December 2019
22 July 2020
17 October 2022
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference